Shuanglu Pharmaceutical (002038.SZ) released its first half-year financial results, with a net profit attributable to the parent company of 1.21 billion yuan, an increase of 309.08%.

Zh tng cijng APP xn, Shungl yoy (002038.SZ) fb 2025 nin bn nind bogo, gi gngs yngy shu r wi 3.05 y yun, tngb jinsho 22.24%Gush y shngsh gngs gdng de jnglr wi 1.21 y yun, tngb zngzhng 309.08%Gush y shngsh gngs gdng de kuch fi jngchngxng sny de jnglr wi 2600.44 wn yun, tngb jinsho 78.42%Jbn mi g shuy wi 0.12 yun. Zhtng Finance APP News, Shuanglu Pharmaceuticals (002038.SZ) released the 2025 interim report, with the company's operating income of 3.05 billion yuan, a year-on-year decrease of 22.24%. The net profit attributable to the shareholders of the listed company was 1.21 billion yuan, a year-on-year increase of 309.08%. The net profit attributable to the shareholders of the listed company after deducting non-recurring gains and losses was 26.0044 million yuan, a year-on-year decrease of 78.42%. Basic earnings per share was 0.12 yuan.